Sapient Capital LLC Invests $291,000 in Henry Schein, Inc. (NASDAQ:HSIC)

Sapient Capital LLC acquired a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 3,839 shares of the company’s stock, valued at approximately $291,000.

Other hedge funds also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. purchased a new position in Henry Schein during the fourth quarter valued at approximately $39,000. Baystate Wealth Management LLC raised its position in shares of Henry Schein by 2,500.0% during the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Henry Schein during the 3rd quarter valued at $46,000. Covestor Ltd lifted its stake in shares of Henry Schein by 88.4% during the 1st quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after buying an additional 404 shares in the last quarter. Finally, RVW Wealth LLC bought a new position in Henry Schein in the 3rd quarter worth $104,000. 96.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Henry Schein

In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $70.73 on Tuesday. The firm has a market capitalization of $9.09 billion, a PE ratio of 22.45, a PEG ratio of 1.76 and a beta of 0.87. The stock’s fifty day moving average is $74.73 and its 200 day moving average is $72.54. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $85.39. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same quarter last year, the business posted $1.21 EPS. Henry Schein’s revenue was down 10.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HSIC shares. JPMorgan Chase & Co. boosted their price objective on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. SVB Leerink started coverage on shares of Henry Schein in a report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective for the company. TheStreet raised shares of Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Barrington Research raised their target price on shares of Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Finally, Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.